| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 101 | Preventing diseases in infants delivered via caesarean section | US14135171 | 2013-12-19 | US09107438B2 | 2015-08-18 | Joachim Schmitt; Bernd Stahl; Jan Knol |
| The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. | ||||||
| 102 | PROBIOTIC FOR ADMINISTRATION TO HEALTHY YOUNG MAMMALS DURING THE WEANING PERIOD FOR IMPROVING TOLERANCE TO NEWLY INTRODUCED FOOD STUFFS | US14232506 | 2012-07-11 | US20140170126A1 | 2014-06-19 | Swantje Duncker; Marie Lewis; Annick Mercenier; Anurag Singh; Michael Bailey |
| The current invention is based upon administration of a probiotic, B. Lactis NCC2818 to healthy young mammals during the critical weaning period (in infants this period is usually from about 3 months to about 12, 18 or 24 months old), so as to accelerate the young mammal's adaptation to new food. The effectiveness of the invention is evidenced herein by morphological and immunological changes observed in a piglet animal model of weaning. Thus, administration of the probiotic according to the invention had a prophylactic effect, preventing the severe discomfort and pathological states associated with the introduction to novel foods during the weaning period. | ||||||
| 103 | Preventing diseases in infants delivered via caesarean section | US12091011 | 2006-10-06 | US08715769B2 | 2014-05-06 | Joachim Schmitt; Bernd Stahl; Jan Knol |
| The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. | ||||||
| 104 | PREVENTING DISEASES IN INFANTS DELIVERED VIA CAESAREAN SECTION | US14135171 | 2013-12-19 | US20140105865A1 | 2014-04-17 | Joachim SCHMITT; Bernd Stahl; Jan Knol |
| The present invention provides the use of a composition comprising non-digestible oligosaccharide for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. | ||||||
| 105 | METHOD FOR IMPROVING THE SURVIVAL RATE OF PROBIOTIC | US13817280 | 2011-08-16 | US20130142908A1 | 2013-06-06 | Anders Henriksson |
| The present invention relates to the improvement of the survival rate of probiotic strains such as Lactobacillus acidophilus or Bifidobacterium ssp. by Lactobacillus strains that enhance the survival rate of probiotic strains in food or feed products. | ||||||
| 106 | USE OF PLANT EXTRACTS AS PREBIOTICS, COMPOSITIONS AND FOODS CONTAINING SUCH EXTRACT | US13428621 | 2012-03-23 | US20120269790A1 | 2012-10-25 | Marcos PEÑALVER MELLADO; José A. LÓPEZ MAS; Sergio A. STREITENBERGER; Pedro MARTINEZ ORTIZ |
| The present invention claims the use of pomegranate (Punica granaturn) plant extracts and various combinations of said extracts, some additionally including a probiotic, which allow a synergistic effect between the bioactive components thereof, for the purpose of preparing dietary supplements, functional foods/beverages, food additives and drugs for use in caring for human health. | ||||||
| 107 | Tetracycline-sensitive bifidobacteria strains | US12447572 | 2007-11-02 | US08226936B2 | 2012-07-24 | Per Stroeman |
| Many probiotic Bifidobacteriacea contains an active tetW that renders the cells resistant to tetracycline. This presents a theoretical risk of a horizontal transfer of functional antibiotic genes. The present invention relates to novel tetracycline-sensitive strains of the well-known probiotic Bifidobacterium animalis subsp. lactis strain BB-12® and the use of such novel strains for the preparation of a food or feed product or a dosage form comprising viable organisms. | ||||||
| 108 | COMPOSITION WITH SYNBIOTICS | US12743806 | 2008-11-20 | US20100330040A1 | 2010-12-30 | Jan Knol; Bernd Stahl |
| Nutritional compositions with health benefits comprising bacterial strains and galactooligosaccharides are disclosed. | ||||||
| 109 | JUICE BEVERAGES WITH PROBIOTIC BACTERIA | US12110746 | 2008-04-28 | US20080299255A1 | 2008-12-04 | Sallie Kim; Lorenzo C. Nicastro |
| Fruit juice beverages comprising probiotic bacteria and fructooligosaccharides may be used for promoting growth of beneficial bacteria in the gut. Methods for preparing the fruit juice beverages are also disclosed. The methods can achieve a long shelf-life while maintaining high levels of bacterial viability. The probiotic bacteria may be added to the beverage in, for example, freeze-dried or frozen form. | ||||||
| 110 | NK 세포 활성을 통한 인플루엔자바이러스 감기 질환 예방과 면역 증강용 발효 조성물의 제조방법 | KR1020160183280 | 2016-12-30 | KR101753164B1 | 2017-07-03 | 남우식; 신동환; 이동석; 원병렬; 이희준; 남보라; 최유정; 김인철 |
| 본발명은 NK 세포활성을통한인플루엔자바이러스감기질환예방과면역증강용발효조성물의제조방법에관한것으로, 탈지분유 3 중량부를기준으로, 우유 70~85 중량부, 정제수 11~27 중량부를 50℃~60℃에서혼합하는우유혼합단계;상기우유혼합단계에서혼합된우유조성물을 90℃내지 100℃에서 25분내지 35분간살균하는살균단계; 상기살균단계에서살균된우유조성물을 8℃내지 12℃로냉각하는냉각단계; 상기냉각단계에서냉각된우유조성물에발효유산균과, 김치유래열처리유산균을접종하는유산균접종단계; 상기유산균접종단계를거친우유조성물을 2시간동안 10℃에서 37℃로상승시키며배양하는예비배양단계; 상기예비배양단계를거친우유조성물을 37℃에서 5시간동안배양하는본 배양단계; 상기본 배양단계를거친우유조성물을 10℃로냉각시키는냉각단계;를포함하되, 상기유산균접종단계에서접종되는발효유산균은중어느하나이상이고, 상기유산균접종단계에서접종되는김치유래열처리유산균은김치에서발생된인기술을제공함으로써 NK 세포활성을증진하는발효유산균이함유된조성물을이용하여다양한음용수또는식품등에첨가하여사람들이쉽게접하고, 섭취할수 있어인플루엔자바이러스감기질환예방할수 있는효과가있다.또한, NK 세포의변화를통하여면역력이증진할뿐만아니라 EPS의함량이일반우유조성물보다 10배가량높아효소를활성시키는등의다양한효과를볼 수있다.그리고, 유산균의함량이높아기능성식품으로상품성이매우높아섭취자의건강을개선시킬수 있는효과도있다. | ||||||
| 111 | 비피도박테리움 박테리아의 투여에 의한 복부 둘레의 감소 방법 | KR1020167001100 | 2008-12-19 | KR1020160011234A | 2016-01-29 | 구필푀유라나탈리; 귀요네드니; 쟈콥슈테판 |
| 본발명은생균제(probiotic), 바람직하게속의박테리아를투여함으로써대상에서복부둘레를감소시키는방법에관한것으로, 상기방법은본 발명의한 측면으로는비치료적인방법이고, 본발명의또 다른측면으로 IBS(irritable bowel syndrome, 과민성대장증후군)를치료하는방법이다. | ||||||
| 112 | 요구르트 및 그의 제조 방법 | KR1020030050870 | 2003-07-24 | KR1020040010363A | 2004-01-31 | 마쯔오까,시게오 |
| PURPOSE: To provide a yogurt made by new lactic acid bacilli having good flavor and having intestinal disorder controlling effect, and to provide a method for producing the yogurt. CONSTITUTION: This method for producing the yogurt comprises use of lactic acid bacilli. The lactic acid bacilli are composed of bacteria comprising Lactococcus lactis sp. lactis, Lactococcus lactis sp. cremoris and bifidobacterium. | ||||||
| 113 | GLYCERIN-BASED GUMMY CANDY AND FOAM CANDY PRODUCTS WITH PROBIOTIC BACTERIA | US15580431 | 2016-06-08 | US20180228179A1 | 2018-08-16 | Mogens DOLMER; Mette WINNING |
| The present invention relates to a glycerin-based candy product comprising probiotic bacteria, said product having a moisture content less than 9% and a water activity (aw) less than 0.5 and comprising a) glycerin in an amount of 10% to 40% (w/w), b) 40% to 75% (w/w) of at least one saccharide or at least one polyol which is not glycerin, or a mixture thereof, c) at least one hydrocolloid, and d) at least one species of a probiotic bacterium. Further, the invention relates to methods for producing a glycerin-based candy product comprising probiotic bacteria. | ||||||
| 114 | BIFIDOBACTERIA FOR TREATING CARDIAC CONDITIONS | US15927986 | 2018-03-21 | US20180207209A1 | 2018-07-26 | REMY BURCELIN; DIDIER CARCANO; SAMPO LAHTINEN; LOTTA STENMAN; JOHN KONHILAS |
| This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of myocardial infarction and congestive heart failure. | ||||||
| 115 | BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS | US15452240 | 2017-03-07 | US20180021391A1 | 2018-01-25 | REMY BURCELIN; DIDIER CARCANO; SAMPO LAHTINEN |
| This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions. | ||||||
| 116 | NOVEL STRAIN OF BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS CECT 8145 AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF EXCESS WEIGHT AND OBESITY AND ASSOCIATED DISEASES | US14905270 | 2014-07-17 | US20160143963A1 | 2016-05-26 | Patricia MARTORELL GUEROLA; Mª Empar CHENOLL CUADROS; Daniel RAMÓN VIDAL; Pepa ORTIZ SERRANO; Silvia LLOPIS PLA; Núria GONZALEZ MARTÍNEZ; Salvador GENOVÉS MARTÍNEZ; Beatriz CASINOS RAMO; Ángela SILVA ANGULO; Amaya ALEIXANDRE |
| The invention is applicable within the food and pharmaceutical industry. More specifically, it relates to a novel strain of the species Bifidobacterium animalis subsp. lactis CECT 8145, the cell components, metabolites and secreted molecules thereof, which, incorporated into food and/or pharmaceutical formulations, can be used in the treatment and/or prevention of excess weight and obesity and related diseases such as metabolic syndrome, hypertension, glycemia, inflammation, type 2 diabetes, cardiovascular diseases, hypercholesterolemia, hormonal alterations, infertility, etc. | ||||||
| 117 | METHOD FOR STIMULATING THE INTESTINAL FLORA | US14973166 | 2015-12-17 | US20160100618A1 | 2016-04-14 | Günther BOEHM; Bernd STAHL; Jan KNOL |
| The present invention relates to methods for feeding and to compositions to be administered to infants delivered via caesarian section and in particular to the use of a) at least two different microorganisms; or b) at least one microorganism and at least one indigestible oligosaccharide; or c)at least two different Bifidobacteria species, subspecies or strains for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. Thereby it is possible to stimulate the healthy development of the intestinal flora of said infants. | ||||||
| 118 | Compositions | US14129851 | 2012-06-30 | US09308271B2 | 2016-04-12 | Birgitte Yde |
| The invention relates to a dry compositions for lactic acid bacteria and in particular to a dry composition comprising from 109 to 1013 cfu/g of the composition of lactic acid bacteria cells, wherein the composition is characterized by that it also comprises following amounts of protective agents (all amounts of protective agents below are given relative to 1 g of lactic acid bacteria cells in the composition): from 6 to 9 g of trehalose, from 0.1 to 1 g of inulin and from 0.5 to 3 g of hydrolyzed casein, and by that it does not comprise a salt of alginic acid. The composition has an improved storage stability of the cell of interest. Comparison experiments have been made between compositions with and without alginate and it has been found that there is substantially no difference between compositions with or without alginate with regard to stability. Further, the invention relates to a method for preparing a dry lactic acid bacteria composition. | ||||||
| 119 | METHOD FOR STIMULATING INTESTINAL BARRIER INTEGRITY AFTER NON-NATURAL BIRTH | US14846120 | 2015-09-04 | US20160058806A1 | 2016-03-03 | Joachim SCHMITT; Günther BOEHM; Christopher BEERMANN |
| The present invention relates to methods for feeding and stimulating the health of infants delivered via caesarean section comprising administering long chain polyunsaturated fatty acids and/or nucleotides. | ||||||
| 120 | PET FOOD COMPOSITION HAVING PROBIOTIC BIFIDOBACTERIUM ANIMALIS | US14136528 | 2013-12-20 | US20150173397A1 | 2015-06-25 | Maria Dolores Martinez Villagran; Rajesh Bund; Isoken Omosefe Igwekala-Nweke |
| A probiotic coated kibble having internal glycerin. | ||||||
QQ群二维码
意见反馈
意见反馈